RxDoctor Payments DataLook up a doctor →

Gregory Fox, MD

Ophthalmology · Lenexa, KSNPI 1225070717

Payments from drug & device makers

$678,218in general payments, 2019–2025

Across 148 payments — averaging $4582.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$485K
  • Eyepoint US, Inc.$179K
  • Bayer$7K
  • Mylan Technologies Inc.$5K
  • AbbVie$580
  • Apellis Pharmaceuticals, Inc.$350
  • plus $1K from 12 others

What the payments were for

  • Travel & lodging$97630%
  • Food & beverage$2,29170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$678,218 in reported general payments places this provider in the 95th percentile of 135 ophthalmology providers in Kansas.

See all ophthalmology providers in Kansas

Medicare billing

Part B allowed, 2024
$5,970,801
Medicare patients
1,283
Services billed
43,814

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProlensaBromfenac Sodium39$13,537
Prednisolone Acetate230$9,666
LumiganBimatoprost16$5,394
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol42$5,213
Ketorolac Tromethamine106$2,277
MoxifloxacinMoxifloxacin Hcl92$2,034
Brimonidine Tartrate37$2,033
Timolol Maleate82$857
Dorzolamide Hcl35$661
Latanoprost66$442
Ofloxacin23$265
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat19$217
ErythromycinErythromycin Base11$105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$28$13,53739 claims
AbbVieLumigan$580$5,39416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 135 ophthalmology providers in Kansas.

Other ophthalmology in Lenexa

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →